Steven Zygmont, MD
Endocrinology, Diabetes & Metabolism · East Syracuse, NYNPI 1114965860
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $148,527 of the $167,168 with a category attached, or 88.8%. 37 manufacturers reported payments, led by AstraZeneca at 39.2% of the total. Reporting peaked in 2019 at $66,578 and has fallen 95.4% since, to $3,090 in 2025. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 421 payments — averaging $397.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$66K
- Novo Nordisk$43K
- Boehringer Ingelheim$31K
- Lilly USA, LLC$20K
- Merck$2K
- Medtronic$2K
- plus $3K from 31 others
What the payments were for
- Consulting fees$2,1941%
- Speaking & faculty fees$148,52789%
- Travel & lodging$7,2904%
- Food & beverage$9,0955%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 87 | $65,580 |
| Novo Nordisk | 88 | $43,163 |
| Boehringer Ingelheim | 65 | $30,929 |
| Lilly USA, LLC | 50 | $19,945 |
| Merck | 4 | $2,476 |
| Medtronic(2 entities) | 16 | $1,863 |
| Abbott | 7 | $413 |
| Amgen(2 entities) | 15 | $412 |
| Tandem Diabetes Care, Inc. | 8 | $328 |
| Insulet Corporation | 16 | $304 |
| Dexcom, Inc. | 4 | $277 |
| Mannkind Corporation | 5 | $197 |
| BETA Bionics, Inc. | 2 | $143 |
| Corcept Therapeutics | 5 | $125 |
| Sanofi-aventis U.S. LLC | 4 | $112 |
| Pfizer | 6 | $106 |
| Xeris Pharmaceuticals, Inc. | 4 | $74 |
| Amneal Pharmaceuticals LLC | 3 | $72 |
| Bayer | 3 | $61 |
| Sequel Med Tech, LLC | 3 | $60 |
| Ascendis Pharma Endocrinology Inc | 2 | $57 |
| Kyowa Kirin, Inc. | 2 | $56 |
| Radius Health, Inc. | 3 | $50 |
| Amphastar Pharmaceuticals, Inc. | 2 | $44 |
| Cequr Corporation | 2 | $42 |
| Chiesi USA, Inc. | 2 | $40 |
| IBSA Pharma Inc. | 2 | $37 |
| Tolmar, Inc. | 2 | $32 |
| Almatica Pharma LLC | 1 | $25 |
| Sandoz | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| AbbVie | 1 | $17 |
| GSK | 1 | $16 |
| Antares Pharma, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$64,457
- JARDIANCE$49,498
- Ozempic$14,797
- RYBELSUS$12,489
- Tresiba$12,082
- STEGLATRO$2,310
- Xultophy 100/3.6$1,755
- MINIMED 780G$1,337
- iLet Bionic Pancreas$353
- FreeStyle Libre 2$188
- t-slim insulin pump$125
- TEPEZZA$114
- Omnipod$107
How this compares
$167,168 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 302 | $506,810 |
| JardianceEmpagliflozin | 177 | $220,829 |
| TrulicityDulaglutide | 113 | $170,874 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 77 | $111,194 |
| MounjaroTirzepatide | 62 | $98,538 |
| Tresiba Flextouch U-200Insulin Degludec | 74 | $97,306 |
| Humalog Kwikpen U-200Insulin Lispro | 32 | $82,225 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $72,121 |
| Tresiba Flextouch U-100Insulin Degludec | 76 | $63,239 |
| JanuviaSitagliptin Phosphate | 43 | $56,710 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 11 | $49,518 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 68 | $46,640 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $45,743 |
| FarxigaDapagliflozin Propanediol | 29 | $40,394 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 178 | $37,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $43,163 | $539,681375 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Baqsimi, Insulin Lispro | $19,945 | $289,821254 claims |
| Boehringer IngelheimJardiance, Tradjenta | $30,929 | $250,337196 claims |
| MerckJanuvia, Janumet Xr | $2,476 | $78,79366 claims |
| AstraZenecaFarxiga | $65,580 | $40,39429 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $112 | $30,07038 claims |
| AbbVieSynthroid | $17 | $10,265118 claims |
| IBSA Pharma Inc.Tirosint | $37 | $4,83419 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $72 | $4,153261 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in East Syracuse
- David DicesarEast Syracuse$255K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.